论文部分内容阅读
两个研究小组在近期出版的《临床肿瘤学杂志》(JCO)上刊文指出,每周给予一次阿法依泊汀(重组人促红细胞生成素)可减轻癌症患者的贫血状况,同时亦改善患者的生活质量和血红蛋白水平,并减少输血需求。来自于美国明尼苏达州罗彻斯特市Mayo医院的Thomas E．Witzig医师报道说,众所周知,阿法依泊汀需要数周时间才能明显增加血红蛋白量；因为在输血或给予阿法依泊汀前,临床检测到的血红蛋白量非常低,癌症患者的低血红蛋白水平通常可持续数周,从而出现疲劳和生活质量低下的状况。
Two research groups recently published in the Journal of Clinical Oncology (JCO) pointed out that once weekly administration of epoetin (recombinant human erythropoietin) can reduce the anemia in cancer patients, but also improve Patient quality of life and hemoglobin levels, and reduce transfusion requirements. Thomas E. from Mayo Hospital, Rochester, Minnesota, USA Dr. Witzig reports that it is well-known that taking epoetin alfa takes weeks to significantly increase the amount of hemoglobin, since the amount of hemoglobin that is clinically detected before transfusions or aloepoepam is very low, the level of low hemoglobin in cancer patients is usually May last several weeks, resulting in fatigue and poor quality of life.